Vernakalant

Drug Profile

Vernakalant

Alternative Names: Brinavess; Kynapid; MK-6621; RSD-1235; vernakalant (IV); vernakalant (oral)

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Cardiome Pharma
  • Class Anisoles; Antiarrhythmics; Cyclohexanes; Pyrrolidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Atrial fibrillation

Most Recent Events

  • 16 Feb 2017 Vernakalant is available for licensing as of 16 Feb 2017. http://cardiome.ca/partners/ (Cardiome Pharma pipeline, February 2017)
  • 13 Feb 2017 The Scottish Medicines Consortium does not recommend using vernakalant withing NHS Scotland for the treatment of Atrial fibrillation
  • 27 Jan 2016 Cardiome files an Orphan Drug Designation application with the US FDA for Atrial fibrillation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top